Contributions
Abstract: 177
Type: Hot Topic
Abstract Category: N/A
Robust evidence indicates that inflammatory, immune-mediated damage is associated with all phases of MS with the development of oligodendroglial and neuronal injury that may result in irreversible neurological dysfunction. Immune intervention offers the prospect of mitigating or ideally completely stopping CNS inflammation in MS.
Alternative treatment strategies include the so-called 'escalation' model, where medication with high safety profile is offered first, and more effective (although riskier) therapeutics are only considered in case of MS disease persistence or breakthrough following the initial treatment(s). In the 'induction' model, a highly effective therapy is offered early, even as first line in the course of disease. According to the induction strategy, the higher treatment-related risk is counterbalanced by a more profound suppression of neuroinflammation at earlier stages, which may potentially improve outcomes in the longer term.
In this Hot Topic presentation, an overview of key players in the immune pathogenesis in MS will be provided, and examples of biological and cytotoxic immunotherapies will be briefly reviewed with special regard to their immunological rationale and effects on the human immune system.
Disclosure: I disclose travel support and speaker honoraria from Bayer HealthCare, Bayer Pharma, Biogen Idec, Merck-Serono and Sanofi Aventis.
Abstract: 177
Type: Hot Topic
Abstract Category: N/A
Robust evidence indicates that inflammatory, immune-mediated damage is associated with all phases of MS with the development of oligodendroglial and neuronal injury that may result in irreversible neurological dysfunction. Immune intervention offers the prospect of mitigating or ideally completely stopping CNS inflammation in MS.
Alternative treatment strategies include the so-called 'escalation' model, where medication with high safety profile is offered first, and more effective (although riskier) therapeutics are only considered in case of MS disease persistence or breakthrough following the initial treatment(s). In the 'induction' model, a highly effective therapy is offered early, even as first line in the course of disease. According to the induction strategy, the higher treatment-related risk is counterbalanced by a more profound suppression of neuroinflammation at earlier stages, which may potentially improve outcomes in the longer term.
In this Hot Topic presentation, an overview of key players in the immune pathogenesis in MS will be provided, and examples of biological and cytotoxic immunotherapies will be briefly reviewed with special regard to their immunological rationale and effects on the human immune system.
Disclosure: I disclose travel support and speaker honoraria from Bayer HealthCare, Bayer Pharma, Biogen Idec, Merck-Serono and Sanofi Aventis.